TABLE 5.
FMDV serotype-specific LPBE titers following sequential immunization with multiple inactivated FMDV serotypesa
| Treatment | Day postvaccination | FMDV serotype-specific serological response (log10 LPBE titer) in the OPA group (n = 4)b |
||||
|---|---|---|---|---|---|---|
| OPA | A22 | A1S | SAT1 | C1 | ||
| Inactivated FMDV OPA vaccination | −1 | 1.20 ± 0.00 | 1.20 ± 0.00 | 1.24 ± 0.03 | 1.20 ± 0.00 | 1.27 ± 0.04 |
| 0 | ||||||
| 6 | 1.20 ± 0.00 | 1.20 ± 0.00 | 1.20 ± 0.00 | 1.20 ± 0.00 | 1.20 ± 0.00 | |
| 20 | 1.84 ± 0.14** | 1.24 ± 0.03 | 1.20 ± 0.00 | 1.24 ± 0.03 | 1.20 ± 0.00 | |
| Inactivated FMDV OPA vaccination | 21 | |||||
| 27 | 2.26 ± 0.17** | 1.31 ± 0.03 | 1.20 ± 0.00 | 1.24 ± 0.03 | 1.28 ± 0.08 | |
| 41 | 2.52 ± 0.13** | 1.39 ± 0.09 | 1.20 ± 0.00 | 1.24 ± 0.03 | 1.50 ± 0.09 | |
| Inactivated FMDV A22 vaccination | 42 | |||||
| 48 | 2.63 ± 0.13** | 1.69 ± 0.09* | 1.20 ± 0.00 | 1.32 ± 0.11 | 1.34 ± 0.00 | |
| 62 | 2.56 ± 0.21** | 2.14 ± 0.13** | 1.20 ± 0.00 | 1.28 ± 0.04 | 1.54 ± 0.07 | |
| Inactivated FMDV A1S vaccination | 63 | |||||
| 69 | 2.71 ± 0.15** | 2.14 ± 0.14** | 2.22 ± 0.29** | 1.58 ± 0.08 | 1.69 ± 0.04 | |
| 83 | 2.63 ± 0.13** | 1.95 ± 0.12** | 2.60 ± 0.34** | 1.81 ± 0.27* | 1.73 ± 0.04* | |
| Inactivated FMDV S1Z vaccination | 84 | |||||
| 90 | 2.63 ± 0.10** | 2.11 ± 0.14** | 2.75 ± 0.31** | 2.14 ± 0.22** | 1.73 ± 0.07* | |
| 97 | 2.67 ± 0.14** | 2.07 ± 0.14** | 2.63 ± 0.34** | 2.33 ± 0.26** | 1.69 ± 0.04 | |
a
LPBE, liquid phase blocking ELISA.
b
Results are expressed as the log10-transformed means ± standard errors of the means (SEMs) of FMDV-specific LPBE titers postvaccination of the groups with duplicate determinations for each animal. Values that are statistically significantly different from the value at −1 day postvaccination (the day before vaccination) by two-way ANOVA analysis with multiple comparison are indicated by asterisks as follows: *, P < 0.05; **, P < 0.001.